Company intelligence / Profile preview

Firebrand Therapeutics

Princeton, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Firebrand Therapeutics originated at least one antisense oligonucleotide antineoplastic program targeting metadherin (MTDH) via gene silencing for cancer; the program has been developed preclinically by Secarna Pharmaceuticals, with pharmacodynamic data reported in preclinical cancer models, but no active clinical development has been reported as of the latest update.[1]

Therapeutic areas: Oncology
Modalities: Antisense oligonucleotide
Industry: Biotech

Partnerships

Secarna Pharmaceuticals[1]

Beyond the preview

Go deeper on Firebrand Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Firebrand Therapeutics.

Explore the full profile